Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Ramucirumab Does Not Prolong PFS in HER2-Negative Metastatic Breast Cancer
December 13th 2013, 3:07pm
San Antonio Breast Cancer Symposium
Antiangiogenic therapy with ramucirumab, an investigational agent that binds to VEGFR-2, added to first-line docetaxel failed to delay the progression of HER2-negative metastatic breast cancer.
CTCs Prognostic But Not Helpful In Switching Therapy in MBC
December 13th 2013, 1:16pm
San Antonio Breast Cancer Symposium
Switching chemotherapy based on level of elevated circulating tumor cells after one cycle of chemotherapy did not improve OS or PFS in women with metastatic breast cancer.
Carboplatin Improves pCR More Than Bevacizumab in TNBC
December 13th 2013, 12:50pm
San Antonio Breast Cancer Symposium
The addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response rates in patients with triple-negative breast cancer.
Idelalisib Improves Survival in High-Risk CLL
December 13th 2013, 11:33am
ASH Annual Meeting and Exposition
Combination treatment with idelalisib plus rituximab was associated with a >70% improvement in OS in patients with high-risk relapsed/refractory CLL.
BOLERO-3 Safety Analysis Finds Everolimus Regimen Is Manageable
December 13th 2013, 10:59am
San Antonio Breast Cancer Symposium
The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.
Dr. McIntyre on Frontline Eribulin in HER2-Negative MBC
December 13th 2013, 10:59am
San Antonio Breast Cancer Symposium
Kristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
Dr. Matthew Ellis Discusses the FALCON Trial
December 13th 2013, 10:10am
San Antonio Breast Cancer Symposium
Matthew J. Ellis, MD, PhD, from the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.
Dr. Edith Perez on T-DM1 and the MARIANNE Trial
December 13th 2013, 10:03am
San Antonio Breast Cancer Symposium
Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 as a treatment for patients with breast cancer.
No Survival Benefit Found in LRT for Women Presenting With Metastatic Breast Cancer
December 13th 2013, 9:43am
San Antonio Breast Cancer Symposium
In women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS),
PIK3CA Mutations Linked to Treatment Resistance in HER2+, HR+ Breast Cancer
December 13th 2013, 9:43am
San Antonio Breast Cancer Symposium
PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR). The lowest pCR was observed in HER2+/hormone receptor-positive (HR+), PIK3CA-mutated tumors.
Dr. Brufsky Discusses the tnAcity Trial in TNBC
December 13th 2013, 9:24am
San Antonio Breast Cancer Symposium
Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.
Quizartinib Active in AML at Lower Doses
December 13th 2013, 9:12am
ASH Annual Meeting and Exposition
Almost half of patients with relapsed/refractory AML had complete remissions when treated with quizartinib, which also had a more favorable safety profile as compared with higher doses.
Exercise Reduces Joint Pain in Breast Cancer Patients Treated With Aromatase Inhibitors
December 13th 2013, 9:03am
San Antonio Breast Cancer Symposium
A prescribed exercise program reduces joint pain in breast cancer survivors taking AIs, with pain reductions observed at all levels of exercise.
Anastrozole Cuts Breast Cancer Incidence in Half for Women at High Risk
December 13th 2013, 8:52am
San Antonio Breast Cancer Symposium
Anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.
Dr. Goy on CAR-Modified T Cells in Lymphoma
December 13th 2013, 8:00am
ASH Annual Meeting and Exposition
Andre Goy, MD, MS, from the John Theurer Cancer Center, discusses the apparent effectiveness of CD19-targeted CAR-modified T cells as a treatment for patients with various types of lymphoma.
NeoALTTO Analysis Finds Significant Link Between pCR and Survival
December 12th 2013, 5:31pm
San Antonio Breast Cancer Symposium
Pathologic complete response to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.
No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer
December 12th 2013, 5:03pm
San Antonio Breast Cancer Symposium
Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.
Brentuximab Vedotin Shows Activity in B-Cell Lymphomas
December 12th 2013, 3:13pm
ASH Annual Meeting and Exposition
Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.
Dasatinib Added to Aromatase Inhibitor Extends PFS in HER2-Negative MBC
December 12th 2013, 1:50pm
San Antonio Breast Cancer Symposium
Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled PFS compared with letrozole alone in women with HR-positive, HER2-negative metastatic breast cancer.
Dr. Arteaga Discusses the CALGB 40603 Trial
December 12th 2013, 11:36am
San Antonio Breast Cancer Symposium
Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.